{
    "2018-03-07": [
        [
            {
                "time": "2018-03-15",
                "original_text": "FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs",
                "features": {
                    "keywords": [
                        "FDA",
                        "Gottlieb",
                        "drug pricing",
                        "high costs"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation",
                "features": {
                    "keywords": [
                        "Biogen",
                        "AbbVie",
                        "Zinbryta",
                        "brain inflammation",
                        "recall"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Zinbrynta Now Connected To Brain Inflammation",
                "features": {
                    "keywords": [
                        "Zinbrynta",
                        "brain inflammation"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-05",
                "original_text": "Why Gilead Sciences’ Harvoni Lost Market Share in 4Q17",
                "features": {
                    "keywords": [
                        "Gilead Sciences",
                        "Harvoni",
                        "market share",
                        "4Q17"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-05",
                "original_text": "Gilead Sciences’ HCV Products: Lower Revenues in 4Q17",
                "features": {
                    "keywords": [
                        "Gilead Sciences",
                        "HCV",
                        "revenues",
                        "4Q17"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-20",
                "original_text": "Johnson & Johnson’s Pharmaceutical Segment in 4Q17",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "pharmaceutical segment",
                        "4Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "Europe's medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug",
                "features": {
                    "keywords": [
                        "Europe",
                        "regulator",
                        "recall",
                        "Biogen",
                        "AbbVie",
                        "multiple sclerosis"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}